The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Background: The Association of British Neurologists (ABN) 2015 guidelines suggested
classifying multiple sclerosis therapies according to their average relapse reduction. We …

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are
associated with an increased risk of infection, which makes treatment of this condition …

Background Different therapeutic strategies are available for the treatment of people with
relapsing‐remitting multiple sclerosis (RRMS), including immunomodulators …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system
characterized by focal or diffuse inflammation, demyelination, axonal loss and …

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease
with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a …